Evaluation of ruxolitinib, a JAK inhibitor, in multiple myeloma
by Impact Journals LLCRuxolitinib exerts its anti-myeloma effects through several mechanisms. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28547A new research perspective titled "
Evaluation of ruxolitinib, a JAK inhibitor, in multiple myeloma
by Impact Journals LLCRuxolitinib exerts its anti-myeloma effects through several mechanisms. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28547A new research perspective titled "